Skip to main content
TipRanks
Go Ultimate75% OFF

Surgery Partners (SGRY) AI Stock Analysis

390 Followers
SGRY

Surgery Partners

(NASDAQ:SGRY)

Select Model
Rating:54Neutral
Price Target:$23.50â–¼(-12.48% Downside)
Action:reiterated
Date:11/10/26

Overall score is held back primarily by weak financial quality (sharp TTM revenue decline, ongoing net losses, and high leverage despite positive free cash flow). The latest earnings call is a support (reaffirmed guidance and leverage-reduction actions), while technicals show an uptrend but with overextended momentum. Valuation remains a headwind due to negative earnings and no dividend yield provided.

Positive Factors
Organic Growth and Physician RecruitmentSame-facility growth and physician recruitment support a durable volume pipeline for the surgical network. More physicians can direct procedures into company facilities, while rising revenue from newer recruits indicates that recruitment investments are translating into expanding utilization over time.
Negative Factors
Elevated Leverage and Interest BurdenHigh leverage and substantial interest expense constrain the cash available for reinvestment, acquisitions, and shareholder returns. They also leave the company more exposed to operating setbacks, making deleveraging progress important for preserving flexibility across the next several quarters.

Surgery Partners (SGRY) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%60%80%SGRY+75.49%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.51B
Dividend Yield
―
Average Volume (3M)
3.94M
Price to Earnings (P/E)
-40.0
Beta (1Y)
1.11
Revenue Growth
2.19%
EPS Growth
50.06%
Country
US
Employees
16,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Surgery Partners Business Overview & Revenue Model

Company Description

Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical ven...

How the Company Makes Money

Surgery Partners primarily makes money by delivering surgical procedures and related services and collecting reimbursement from third-party payors and patients. Key revenue streams generally include: (1) Facility services revenue: fees earned by its...

Surgery Partners Earnings Call Summary

Earnings Call Date:Aug 10, 2026(Q2-2026)|% Change Since:72.89%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call emphasized healthy organic performance (revenue growth, strong same-facility metrics, physician recruiting, case acuity expansion, sequential expense improvements) and a strategic portfolio optimization (Idaho Falls sale) expected to simplify the business, improve cash conversion and reduce leverage. Headwinds include a modest decline in adjusted EBITDA and margins year-to-date, higher interest expense, a ~350 bps decline in commercial mix, elevated leverage metrics, and muted M&A activity in 2026. On balance, the positives (organic growth, operational improvements, substantial deleveraging transaction and reaffirmed guidance) outweigh the negatives.

Positive Updates

Quarterly Revenue Growth
Net revenue of approximately $849M in Q2 2026, up 2.7% year-over-year; year-to-date net revenue of ~$1.66B, up 3.6% year-over-year.

Negative Updates

Adjusted EBITDA Decline and Margin Pressure
Q2 adjusted EBITDA was approximately $125M versus ~$129M in prior-year quarter (decline). Year-to-date adjusted EBITDA ~$228M, down 2.3% year-over-year; YTD adjusted EBITDA margin 13.7% vs 14.5% prior year.

Company Guidance

Surgery Partners reaffirmed full-year 2026 guidance of revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million (excluding any impact from the pending Idaho Falls transaction) and said it will update guidance promptly after that sale closes; the Idaho Falls transaction is expected to yield approximately $795 million of gross proceeds and reduce consolidated leverage by roughly 0.3 turns. For context, reported Q2 net revenue was about $849 million (up 2.7% YoY) with adjusted EBITDA of about $125 million and a 14.7% adjusted EBITDA margin, while year-to-date net revenue was about $1.66 billion (up 3.6%) with adjusted EBITDA of about $228 million; excluding Idaho Falls, Q2 revenue would have been roughly $660 million with adjusted EBITDA of roughly $98 million (H1 ex-Idaho Falls: ~$1.29 billion revenue and ~$173 million adjusted EBITDA). At quarter end liquidity and leverage metrics included cash of ~$217 million, revolver borrowings of ~$75 million with ~$618 million available capacity, credit-agreement net debt leverage of ~4.4x (balance-sheet net debt/EBITDA ~5.1x), Q2 operating cash flow of ~$59 million (YTD ~$71 million), and Q2 interest of ~ $90 million.

Surgery Partners Financial Statement Overview

Summary

Financial profile is mixed: operating profitability is solid (TTM EBIT margin ~12.0%, EBITDA margin ~14.6%) and free cash flow is positive (TTM FCF ~$202.8M), but TTM revenue declined sharply (-18.4%), the company is still net-loss making (TTM net margin ~-2.6%), and leverage remains elevated (debt ~$3.31B vs equity ~$1.66B; debt-to-equity ~2.0x), constraining flexibility.

Income Statement

46Neutral

Balance Sheet

40Negative

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.36B3.31B3.11B2.74B2.54B2.23B
Gross Profit709.10M765.00M745.60M647.50M574.90M491.40M
EBITDA667.40M565.50M501.40M446.10M460.00M401.00M
Net Income-87.00M-77.90M-168.10M-11.90M-54.60M-70.90M
Balance Sheet
Total Assets7.05B8.12B7.89B6.88B6.68B6.12B
Cash, Cash Equivalents and Short-Term Investments354.50M239.90M269.50M195.90M282.90M389.90M
Total Debt3.31B4.02B3.70B3.06B2.93B3.29B
Total Liabilities4.15B4.59B4.25B3.51B3.40B3.82B
Stockholders Equity1.66B1.71B1.79B1.99B2.00B1.09B
Cash Flow
Free Cash Flow202.80M195.60M209.70M205.00M78.20M29.50M
Operating Cash Flow277.90M274.30M300.10M293.80M158.80M87.10M
Investing Cash Flow308.70M-246.60M-488.50M-225.60M-307.90M-331.70M
Financing Cash Flow-435.50M-57.30M262.00M-155.20M42.10M316.30M

Surgery Partners Technical Analysis

Technical Analysis SentimentPositive
Last Price26.85

Price Trends

50DMA17.81Positive
100DMA16.57Positive
200DMA15.21Positive

Market Momentum

MACD2.82Negative
RSI87.84Negative
STOCH91.17Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGRY, the sentiment is Positive. The current price of 26.85 is above the 20-day moving average (MA) of 23.31, above the 50-day MA of 17.81, and above the 200-day MA of 15.21, indicating a bullish trend. The MACD of 2.82 indicates Negative momentum. The RSI at 87.84 is Negative, neither overbought nor oversold. The STOCH value of 91.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGRY.

Surgery Partners Risk Analysis

Surgery Partners disclosed 49 risk factors in its most recent earnings report. Surgery Partners reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our executive officers and directors may have interests in the proposed Merger that are different from, or in addition to, those of our stockholders generally.Q3, 2026
2.Even if the Merger is completed, our stockholders will remain subject to certain risks relating to the Merger.Q3, 2026
3.We may not complete the Merger within the anticipated timeframe, or at all, which could have a material adverse impact on our business, financial condition or results of operations, as well as negatively impact the per share price of our common stock.Q3, 2026

Surgery Partners Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SGRY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
THCTHC87Outperform$22.45B8.1660.60%―6.23%136.09%
UHSUHS76Outperform$11.07B8.0119.54%0.42%8.00%13.14%
ARDTARDT68Neutral$2.50B17.089.48%―2.03%-28.50%
HCAHCA64Neutral$104.69B16.52-100.45%0.61%5.82%16.59%
SGRYSGRY54Neutral$3.51B-40.04-5.17%―2.19%50.06%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CYHCYH44Neutral$284.87M7.57-2.51%―-7.84%-88.93%

* Healthcare Sector Average

Performance Comparison

0%50%100%SGRYCYHHCATHCUHSARDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SGRY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SGRYSurgery Partners Inc.26.8511.1470.91%
CYHCommunity Health Systems2.02-0.88-30.34%
HCAHca Healthcare501.1923.404.90%
THCTenet Healthcare Corp.282.0787.8245.21%
UHSUniversal Health Services191.98-34.97-15.41%
ARDTArdent Health Partners, Inc.17.759.12105.68%

Surgery Partners Corporate Events

M&A TransactionsRegulatory Filings and Compliance

Surgery Partners Amends Merger Agreement, Reaffirms HealthSpan Transaction

Positive
Nov 9, 2026

On November 8, 2026, Surgery Partners entered an amendment to its merger agreement with HealthSpan Partners after receiving an unsolicited third-party proposal on November 3, updated November 8. The amendment increased the cash consideration to $25 p...

Business Operations and StrategyDelistings and Listing ChangesM&A Transactions

Surgery Partners to be acquired by HealthSpan Partners

Positive
Oct 26, 2026

On October 23, 2026, Surgery Partners agreed to be acquired by HealthSpan Partners, an affiliate of Bon Secours Mercy Health, through a merger that will take the surgical services company private. The all-cash transaction values Surgery Partners at a...

Business Operations and StrategyFinancial DisclosuresM&A Transactions

Surgery Partners Divests Hospital Assets to Cut Debt

Positive
Sep 17, 2026

On September 14, 2026, Surgery Partners completed the sale of Mountain View Hospital, Idaho Falls Community Hospital, and associated subsidiaries to Intermountain Health for approximately $796.6 million in aggregate consideration, following physician...

Business Operations and StrategyFinancial DisclosuresM&A Transactions

Surgery Partners Reports Modest Q2 Revenue Growth, Net Loss

Neutral
Aug 10, 2026

On August 10, 2026, Surgery Partners reported that second-quarter 2026 revenue rose 2.7% year over year to $848.9 million, driven by a 5.0% increase in same-facility revenue and modest growth in case volumes, while adjusted EBITDA dipped to $125.2 mi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026